Dermatology最新文献

{"title":"A Genome-Wide Association Study of Hidradenitis Suppurativa from the VA's Million Veteran Program.","authors":"Zachary D Wendland, Craig C Teerlink, Kathryn M Pridgen, Sydney Lo, Christopher Sayed, Kelsey R van Straalen, Catherine Tcheandjieu, Philip S Tsao, Kyong-Mi Chang, Yun Li, Karen L Mohlke, Quan Sun, Julie A Lynch, Noah Goldfarb","doi":"10.1159/000550386","DOIUrl":"10.1159/000550386","url":null,"abstract":"<p><p><p>Introduction: Data from family and twin studies as well as prior genome-wide association meta-analyses suggest that hidradenitis suppurativa (HS) has a hereditary component. This GWAS identifies genetic variants associated with HS.</p><p><strong>Methods: </strong>Individuals with a diagnosis of HS (defined as at least one instance of ICD9 705.83 or ICD10 L73.2) were identified within the Million Veteran Program. Multi-population and population-specific (African, European, and Hispanic ancestries) case-control genome-wide association studies (GWAS) were performed. Lead single-nucleotide polymorphisms were investigated in external resources providing phenome-wide associations (PheWAS), including UK Biobank, HugeAMP, and FinnGen. Demographic and clinical data for cases and controls were taken from the Corporate Data Warehouse and differences between the cases and control group were analyzed.</p><p><strong>Results: </strong>A total of 4,959 participants with HS were identified among 597,819 MVP participants. The multi-population GWAS identified two significant (p < 5 × 10-8) loci associated with HS, including a novel HS-related variant on chromosome 6 near HLA-DRB1 (lead variant rs679242), and confirmed a previously identified locus on chromosome 17 near SOX9 (rs55811634). The following previously identified loci associated with HS achieved suggestive evidence for association (p < 1 x 10-3): rs17090189 (13q22.1; near KLF5), rs10816701 (9q31.3; near KLF4), rs121908120 (2q35; WNT10A), and rs17103088 (14q24.3; near TMED10).</p><p><strong>Conclusion: </strong>The analysis of the MVP resource for HS identified a novel signal on chromosome 6 near HLA-DRB1 and identified significant evidence and suggestive evidence for several previously reported signals for HS. </p>.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"418-428"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening Practice of Cardiovascular Risk and Psoriatic Arthritis among Patients with Psoriasis in Primary Care.","authors":"Yasmine Khaldi, Lone Skov, Claus Zachariae, Morten Bahrt Haulrig, Fie Astrup, Christopher Willy Schwarz, Nikolai Loft","doi":"10.1159/000551233","DOIUrl":"10.1159/000551233","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is associated with increased risks of cardiovascular disease (CVD) and psoriatic arthritis (PsA). In Denmark, general practitioners (GPs) are responsible for annual screening, but validated tools for PsA screening are not consistently endorsed. Therefore, we evaluated the awareness and screening practices for CVD and PsA among patients with psoriasis among Danish GPs.</p><p><strong>Methods: </strong>In a nationwide cross-sectional survey, 490 randomly selected Danish GPs were invited to complete a questionnaire on awareness and screening practices related to CVD and PsA in patients with psoriasis. Responses were analysed descriptively.</p><p><strong>Results: </strong>A total of 101 GPs responded (21%). Most were aware of increased CVD risk (84%), and 60% reported screening for CVD, primarily assessing blood pressure, BMI, smoking status, and cholesterol. In contrast, only 32% reported screening for PsA.</p><p><strong>Conclusions: </strong>CVD awareness and screening among Danish GPs are relatively high, whereas PsA screening is infrequent. Clearer guidance and simple screening tools may improve early detection of PsA.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"482-484"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors.","authors":"Naraporn Somboonna, Patcharapong Rujirawan, Tiwanun Promvaranon, Chanidapa Wongtada, Jidapa Triwatcharikorn, Natcha Chottawornsak, Kornphaka Kantikosum, Lampet Wongsaroj, Napa Parinyanitikul, Yuda Chongpison, Direkrit Chiewchengchol, Pawinee Rerknimitr","doi":"10.1159/000551797","DOIUrl":"10.1159/000551797","url":null,"abstract":"<p><strong>Introduction: </strong>Epidermal growth factor receptor inhibitors (EGFRIs) are targeted therapies for solid cancers. Their use is associated with cutaneous adverse events (cAEs). This study aimed to investigate cAEs and changes in skin biophysics reflecting the skin barrier function, alterations in antimicrobial peptides (AMPs), and the skin microbiome in patients undergoing treatment with EGFRIs.</p><p><strong>Methods: </strong>A 2-year prospective cohort study was conducted involving patients receiving EGFRIs for solid cancers. cAEs and skin biophysical properties, including transepidermal water loss (TEWL), skin pH, elasticity, sebum, and pigmentation, were measured at baseline and follow-up visits up to 48 weeks. AMPs were assessed using a tape-stripping technique from the cheeks at months 0, 1, and 6, with protein assays and ELISA to determine the levels of human beta-defensin (hBD)-3 and ribonuclease (RNase)-7. Skin microbiome analysis was performed through 16S rRNA sequencing of cheek swabs collected at months 0, 1, and 6.</p><p><strong>Results: </strong>Eighty-four patients were enrolled. The cumulative incidence of cAEs was 94.05%. Skin biophysical properties showed significantly increased TEWL and pH, decreased pigmentation, and no significant changes in elasticity and sebum. AMP analysis from 15 patients revealed significant reduction of RNase-7 levels after 6 months into EGFRIs, while hBD-3 level change was insignificant. A microbiome study from 18 patients showed statistically increased Corynebacterium kroppenstedtii at months 1 and 6, while Cutibacterium acnes, Corynebacterium aurimucosum, Staphylococcus epidermidis, and Staphylococcus aureus were not significantly different among groups.</p><p><strong>Conclusion: </strong>Treatment with EGFRIs compromises skin barrier function and AMP production, leading to skin microbiota changes.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"457-470"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Validation of the Quality of Life Relevance-Acne Questionnaire.","authors":"Pavel V Chernyshov, Servando E Marron, Michael J Boffa, Nives Pustišek, Dimitra Koumaki, Razvigor Darlenski, Tetiana Pochynok, Svitlana Vozianova, Ivan P Chernyshov, Petra Magri Gatt, Navami Pavithra Samaranayake, Andrii V Chernyshov, Lucia Tomas-Aragones","doi":"10.1159/000549544","DOIUrl":"10.1159/000549544","url":null,"abstract":"<p><strong>Introduction: </strong>An acne-specific questionnaire Quality of Life Relevance-Acne (QOLRELEVANCE-ACNE) was developed to evaluate health-related quality of life based on the most relevant topics for acne patients. The aim of the present study was to undertake an international validation of the QOLRELEVANCE-ACNE questionnaire and to propose a severity grading system for its scores.</p><p><strong>Methods: </strong>Patients with acne were asked to fill in the QOLRELEVANCE-ACNE and Dermatology Life Quality Index (DLQI) questionnaires. Global acne severity was assessed independently by both dermatologists and patients. Cronbach's alpha was used for assessment of internal consistency of the QOLRELEVANCE-ACNE questionnaire. Spearman rank correlation was used to study convergent validity and test-retest reliability of the QOLRELEVANCE-ACNE questionnaire. DLQI severity banding system and global acne severity grades were applied to develop variants of the scoring system for the QOLRELEVANCE-ACNE questionnaire.</p><p><strong>Results: </strong>The results of 726 patients with acne across seven countries (Bulgaria, Ukraine, Greece, Spain, Sri Lanka, Croatia, and Malta) were analysed. Cronbach's alpha was 0.94 for the entire QOLRELEVANCE-ACNE questionnaire, 0.90 for the socioemotional, 0.88 for the symptoms, and 0.76 for the stigma and suicidal thoughts domains. The QOLRELEVANCE-ACNE questionnaire showed high test-retest reliability (r = 0.96, p < 0.001) and strong correlation with DLQI scores (r > 0.6, p < 0.001 in all countries). The following grading system of the QOLRELEVANCE-ACNE questionnaire scores was accepted: total scores <20 indicate a mild effect, scores from 20 to 30 indicate a moderate effect and scores >30 indicate a severe effect on a patient's life.</p><p><strong>Conclusion: </strong>Simultaneous international validation of the QOLRELEVANCE-ACNE questionnaire confirmed its convergent validity, internal consistency and test-retest reliability. A grading system of the QOLRELEVANCE-ACNE questionnaire scores was accepted.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"42-48"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic Differences in Hidradenitis Suppurativa: Comorbidities, Lesion Distribution, and Disease Severity in a Taiwanese Population.","authors":"Tsung-Hsien Chang, Wei-Ting Liu, Chao-Chun Yang, Paul-Chen Hsieh, Chia-Bao Chu, Yi-Hua Liao","doi":"10.1159/000549610","DOIUrl":"10.1159/000549610","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory debilitating disorder showing ethnic heterogeneity in its clinical presentation and associated comorbidities. However, data on East Asian populations remain scarce.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of clinical records for patients with HS diagnosed between 2006 and 2022 at two tertiary referral hospitals in Taiwan. Age- and sex-matched reference individuals without HS (3:1 ratio) were randomly selected from dermatology outpatients. Association between comorbidities and HS were analyzed using conditional logistic regression, while logistic regression identified predictors for lesion distribution and disease severity.</p><p><strong>Results: </strong>A total of 512 patients with HS and 1,536 reference individuals were identified. Comorbidities independently associated with HS were obesity, smoking, and diabetes. Men had 4.2 times the odds of developing gluteal lesions but only 0.5 times the odds of axillary or inguinal involvement compared to women. Current smokers had 2.8 times the odds of gluteal involvement but 0.6 times the odds of having axillary lesions. A significant association was observed between obesity and axillary involvement. Advanced disease (Hurley stage II and III) was significantly associated with male sex, smoking, and axillary involvement.</p><p><strong>Conclusion: </strong>Our study highlights distinct lesion distribution in East Asian patients with HS. Male sex and active smoking could predict for gluteal involvement, while female sex and obesity for axillary involvement. Independent risk factors for advanced disease were male sex, smoking, and axillary involvement.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"68-77"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of All Patients with Multiple Actinic Keratoses Requires Lifelong Follow-Up and Repeated Treatment Cycles: A 12-Year Prospective Observational Study of a Cohort of 81 Patients.","authors":"Piergiacomo Calzavara-Pinton, Mariachiara Arisi, Luca Bettolini, Sara Rovaris, Vincenzo Maione, Simone Soglia, Mariateresa Rossi, Marina Venturini, Stefano Bighetti","doi":"10.1159/000548336","DOIUrl":"10.1159/000548336","url":null,"abstract":"<p><strong>Introduction: </strong>Many treatments for multiple actinic keratoses (mAKs) have been proven effective in clinical trials. However, there is a lack of evidence regarding the long-term impact of therapies on disease progression in patients with mAKs. This study aimed to investigate the long-term clinical trajectory of mAKs patients undergoing repeated topical interventions and to evaluate the clinical effectiveness of these treatments and patients' adherence to an extended follow-up protocol in a real-world setting.</p><p><strong>Methods: </strong>We conducted a prospective follow-up of a cohort comprising 81 treatment-naïve mAKs patients from 2012 to 2023. Patients received examinations and, when necessary, interventions every 6 months. Instances of treatment cycle discontinuation and refusals to continue with specific therapies were systematically recorded. Descriptive statistics alongside the Student's t test were employed to evaluate improvements in the Physician Global Assessment (PGA) scores following treatment with the same medication.</p><p><strong>Results: </strong>The average total number of medical examinations and treatments administered per patient was 23.0 ± 0.4 and 16.1 ± 2.4, respectively. Annually, the average number of examinations and treatments per patient was 1.9 ± 0.1 and 1.3 ± 0.2, respectively. We completed 539 (41.6%) treatment cycles using photodynamic therapy with red light and methyl aminolevulinate (MAL-PDT), 182 (14.0%) with diclofenac plus hyaluronate (DHA), 97 (7.5%) with imiquimod (IMI), 101 (7.8%) with 5-fluorouracil (5-FU), 25 (1.9%) with FU, and 353 (27.2%) with cryosurgery. PGA values indicated a statistically significant reduction following each treatment at the 30-day post-treatment mark; however, these values exhibited an increase by the 6-month follow-up visit. The rates of treatment cycle discontinuation were as follows: 28.0% with MAL-PDT, 22.0% with DHA, 27.8% with IMI, 22.8% with 5-FU, and 24.0% with FU. Refusal rates for subsequent treatment cycles with the same drug were documented as 32.7% for MAL-PDT, 17.6% for DHA, 24.7% for IMI, 21.8% for 5-FU, 20.0% for FU, and 12.2% for cryotherapy. Throughout the study duration, 223 cases of squamous cell carcinoma (SCC), 46 cases of basal cell carcinoma (BCC), and 4 malignant melanomas (MMs) emerged on the face or scalp, along with 71 SCCs, 64 BCCs, and 8 MMs in other body regions.</p><p><strong>Conclusion: </strong>Immunocompetent patients with mAKs require lifelong follow-up accompanied by repeated treatment cycles, as the clearance rates, regardless of the degree achieved after a single treatment cycle, tend to be temporary. These patients are at a heightened risk of developing skin tumors.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"49-57"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Phenotype Transition in Pemphigus May Suggest Undertreatment with Rituximab: Findings from a Retrospective Single-Centre Analysis of Relapsed Patients.","authors":"Anne-Lise Strandmoe, Marjolein A J Hiel, Joost M Meijer, Laura L van Nijen-Vos, A Miranda Nijenhuis, L Joost van Pelt, Gonnie H J Meijer, Peter Heeringa, Gilles F H Diercks, Jeroen Bremer, Barbara Horváth","doi":"10.1159/000550300","DOIUrl":"10.1159/000550300","url":null,"abstract":"<p><p><p>Introduction: Pemphigus is an autoimmune bullous disease caused by autoantibodies against desmoglein (DSG) 1 and/or 3 and comprises two main subtypes: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV affects the skin and/or mucosa and includes two forms: mucocutaneous PV (mcPV; anti-DSG1 and anti-DSG3) and mucosal PV (mPV; anti-DSG3). PF, characterized by anti-DSG1 autoantibodies, is limited to the skin. Pemphigus is effectively treated with rituximab, a B-cell-depleting therapy. However, about half of patients relapse, with a subset exhibiting a shift in clinical subtype following relapse, known as clinical phenotype transition. This study aimed to investigate clinical phenotype transition in relapsed pemphigus patients following rituximab treatment.</p><p><strong>Methods: </strong>A single-centre, exploratory retrospective cohort study was conducted, reviewing the medical records of patients with pemphigus who received at least one treatment cycle of rituximab between December 2006 and December 2023. Clinical and immunological data were collected at several time points during the first cycle of rituximab treatment.</p><p><strong>Results: </strong>A total of 109 patients were included, of whom 44% (48/109) achieved sustained complete remission, while 56% (61/109) experienced relapse. Among the 61 patients who relapsed, 26% (16/61) experienced a clinical phenotype transition. All had an initial diagnosis of mcPV. Among these, 75% (12/16) transitioned from mcPV to mPV and 25% (4/16) from mcPV to PF. Clinical phenotype transitioned patients often remained seropositive for anti-DSG3 at clinical remission, a pattern not observed in patients who did not experience a clinical phenotype transition.</p><p><strong>Conclusions: </strong>Clinical phenotype transition was observed exclusively in mcPV patients, suggesting that such changes do not represent a true alteration in disease subtype but rather reflect persistent activity of the same pathogenic autoantibody due to suboptimal B-cell depletion, suggesting undertreatment with rituximab. These findings support the need to refine rituximab treatment regimens to achieve complete B-cell depletion, reduce relapse rates, and optimize long-term disease control in pemphigus. </p>.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"296-309"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12991809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Clinical and Histological Analysis of Bullous Pemphigoid: Immunotherapy-Associated versus Spontaneous Onset Cases.","authors":"Thilo Gwerder, Reinhard Dummer, Thomas Kuendig, Jivko Kamarachev, Lukas Kraehenbuehl","doi":"10.1159/000552077","DOIUrl":"10.1159/000552077","url":null,"abstract":"<p><p><p>Introduction: Immune checkpoint blockade (ICB) therapy can be associated with the development of bullous pemphigoid (BP). To characterize clinical, histological, and serological characteristics, we compared immune-related bullous pemphigoid (irBP) and spontaneous bullous pemphigoid (sBP) considering clinical, serological, and histopathological character.</p><p><strong>Methods: </strong>149 BP patients treated at the University Hospital Zurich between 2015 and 2024 were identified retrospectively. Demographic and serological data were obtained from electronic records. Hematoxylin-eosin-stained biopsies were semi-quantitatively evaluated for immune cell infiltrates, split formation, and infiltration patterns.</p><p><strong>Results: </strong>From the total of 149 cases, 17 were irBP and 132 were sBP. Patients affected by irBP were predominantly males (94%), females were slightly overrepresented in sBP (51.5%) and BP was less often suspected at presentation (59% vs. 85% in sBP). Anti-BP230 antibodies were more frequently elevated in sBP (64.4% vs. 23.5% in irBP). Histologically, irBP cases showed denser eosinophilic and lymphocytic infiltrates, as assessed by semi-quantitative scoring.</p><p><strong>Conclusion: </strong>irBP differs from sBP by showing denser immune-infiltrates, lower rates of elevated anti-BP230 antibodies and predominantly affect males. These observations suggest that irBP represents a distinct subtype and highlight the need for diagnostic awareness in the setting of ICB therapy. </p>.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"501-507"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Do You Want to See a Dermatologist?","authors":"Jette Marcussen, Barry McGrath, Gregor B E Jemec","doi":"10.1159/000546915","DOIUrl":"10.1159/000546915","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-2"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Skin Barrier Monitoring Technology in the Early Prediction of Incontinence-Associated Dermatitis: A Prospective Observational Study.","authors":"Lulu Lin, Yuxin Wang, Jijie Jin, Yingyu Wang, Jiaying Lou, Pan Huang, Xiaoqiong Jiang, Qixia Zhang, Fuman Cai","doi":"10.1159/000548722","DOIUrl":"10.1159/000548722","url":null,"abstract":"<p><strong>Introduction: </strong>Assessing the risk of incontinence-associated dermatitis (IAD) in clinical settings can be subjective, which makes early detection difficult. We aim to verify the ability of skin barrier monitoring technology (SBMT) in predicting IAD.</p><p><strong>Methods: </strong>This was a cohort study. Using a convenience sampling method, 282 patients who were admitted to adult intensive care units were included in the study and were monitored for 7 days or until the day of IAD (less than 7 days). The risk of IAD was assessed with the perineal assessment tool (PAT), and skin barrier indicators of the perianal area were measured with a skin barrier instrument once a day.</p><p><strong>Results: </strong>SBMT was better at predicting early IAD than the perineal assessment tool. Relative transepidermal water loss (R-TEWL) was positively correlated with the risk of IAD. Based on the optimal cutoff value for R-TEWL (47.5 g/m2h), the Kaplan-Meier survival curve showed that the incidence of IAD in the high-risk group was 9.701-fold higher than that in the low-risk group (hazard ratio: 9.701, 95% confidence interval: 4.560-20.640; p < 0.001).</p><p><strong>Conclusion: </strong>SBMT can objectively and accurately predict IAD.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"215-224"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}